These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38668534)

  • 1. Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D.
    Gherlan GS; Lazar SD; Culinescu A; Smadu D; Vatafu AR; Popescu CP; Florescu SA; Ceausu E; Calistru PI
    Trop Med Infect Dis; 2024 Mar; 9(4):. PubMed ID: 38668534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression.
    Jachs M; Panzer M; Hartl L; Schwarz M; Balcar L; Camp JV; Munda P; Mandorfer M; Trauner M; Aberle SW; Zoller H; Reiberger T; Ferenci P
    JHEP Rep; 2023 Aug; 5(8):100751. PubMed ID: 37360907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
    Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
    Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.
    Bahcecioglu IH; Ispiroglu M; Demirel U; Yalniz M
    Hepat Mon; 2015 Mar; 15(3):e24366. PubMed ID: 25861318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
    Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
    Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
    Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
    Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
    Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial.
    Abbas Z; Memon MS; Umer MA; Abbas M; Shazi L
    World J Hepatol; 2016 May; 8(14):625-31. PubMed ID: 27190579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
    Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
    Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
    Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
    J Hepatol; 2024 May; ():. PubMed ID: 38734383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
    Samiullah S; Bikharam D; Nasreen
    World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
    Dietz-Fricke C; Tacke F; Zöllner C; Demir M; Schmidt HH; Schramm C; Willuweit K; Lange CM; Weber S; Denk G; Berg CP; Grottenthaler JM; Merle U; Olkus A; Zeuzem S; Sprinzl K; Berg T; van Bömmel F; Wiegand J; Herta T; Seufferlein T; Zizer E; Dikopoulos N; Thimme R; Neumann-Haefelin C; Galle PR; Sprinzl M; Lohse AW; Schulze Zur Wiesch J; Kempski J; Geier A; Reiter FP; Schlevogt B; Gödiker J; Hofmann WP; Buggisch P; Kahlhöfer J; Port K; Maasoumy B; Cornberg M; Wedemeyer H; Deterding K
    JHEP Rep; 2023 Apr; 5(4):100686. PubMed ID: 37025462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
    Sandmann L; Yurdaydin C; Deterding K; Heidrich B; Hardtke S; Lehmann P; Bremer B; Manns MP; Cornberg M; Wedemeyer H; Maasoumy B;
    Hepatol Commun; 2022 Mar; 6(3):480-495. PubMed ID: 34561972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.